Actively Recruiting
Study of Nicotinamide Mononucleotide with or without Trimethylglycine to Improve Exercise Tolerance and Aging Biomarkers in Healthy Older Adults
Led by Scott Silveira · Updated on 2026-10-07
40
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of nicotinamide mononucleotide NMN combined with trimethylglycine TMG supplementation compared to NMN alone in healthy older adults aged 60 to 80 years. This randomized, double-blind, placebo-controlled, two-arm crossover clinical trial aims to assess safety and efficacy in improving exercise tolerance and influencing biomarkers of aging. The study focuses on physiological and biological activity under controlled exercise conditions. Participants will take oral doses twice daily, either NMN with TMG 1000 mg NMN and 500 mg TMG or NMN alone 1000 mg. The trial uses a crossover design where participants receive one treatment for four weeks, followed by a washout period, then switch to the other treatment for another four weeks. Placebo periods are included for comparison. The supplements are self-administered each morning and evening with water. During the study, participants undergo exercise testing involving constant work rate cycle ergometry to measure time to fatigue, which is the primary outcome. Secondary outcomes include peak oxygen uptake, lactate threshold, anaerobic work capacity, critical power, and levels of circulating NAD and related metabolites. Assessments take place at the beginning and end of each four-week treatment period. Participants attend at least four in-person laboratory visits and are monitored for safety throughout the trial.
CONDITIONS
Brief Title
Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here